Analysis | Metabolite Name | Measured Value | Units | Cell Type | Stimulation |
---|---|---|---|---|---|
Reversed phase POSITIVE ION MODE | N-ACETYLPUTRESCINE (CAS# 18233-70-0); (M+H)+ | 53811 | Peak area | HAHA | IL-17A |
Reversed phase POSITIVE ION MODE | N-ACETYLPUTRESCINE (CAS# 18233-70-0); (M+H)+ | 56606 | Peak area | BS4 | IL-17A |
Reversed phase POSITIVE ION MODE | N-ACETYLPUTRESCINE (CAS# 18233-70-0); (M+H)+ | 59794 | Peak area | BS4 | IFN-G |
Reversed phase POSITIVE ION MODE | N-ACETYLPUTRESCINE (CAS# 18233-70-0); (M+H)+ | 62387 | Peak area | HAHA | Untreated |
Reversed phase POSITIVE ION MODE | N-ACETYLPUTRESCINE (CAS# 18233-70-0); (M+H)+ | 64118 | Peak area | HAHA | TNF-alpha+IL-17A |
Reversed phase POSITIVE ION MODE | N-ACETYLPUTRESCINE (CAS# 18233-70-0); (M+H)+ | 64489 | Peak area | PAK | IL-17A |
Reversed phase POSITIVE ION MODE | N-ACETYLPUTRESCINE (CAS# 18233-70-0); (M+H)+ | 67293 | Peak area | PAK | IFN-G |
Reversed phase POSITIVE ION MODE | N-ACETYLPUTRESCINE (CAS# 18233-70-0); (M+H)+ | 71352 | Peak area | BS4 | Untreated |
Reversed phase POSITIVE ION MODE | N-ACETYLPUTRESCINE (CAS# 18233-70-0); (M+H)+ | 72312 | Peak area | PAK | TNF-alpha |
Reversed phase POSITIVE ION MODE | N-ACETYLPUTRESCINE (CAS# 18233-70-0); (M+H)+ | 72503 | Peak area | BS4 | TNF-alpha+IL-17A |
Reversed phase POSITIVE ION MODE | N-ACETYLPUTRESCINE (CAS# 18233-70-0); (M+H)+ | 74533 | Peak area | HAHA | TNF-alpha |
Reversed phase POSITIVE ION MODE | N-ACETYLPUTRESCINE (CAS# 18233-70-0); (M+H)+ | 80640 | Peak area | BS4 | TNF-alpha |
Reversed phase POSITIVE ION MODE | N-ACETYLPUTRESCINE (CAS# 18233-70-0); (M+H)+ | 88472 | Peak area | PAK | TNF-alpha+IL-17A |
Reversed phase POSITIVE ION MODE | N-ACETYLPUTRESCINE (CAS# 18233-70-0); (M+H)+ | 89422 | Peak area | PAK | Untreated |
Reversed phase POSITIVE ION MODE | N-ACETYLPUTRESCINE (CAS# 18233-70-0); (M+H)+ | 113566 | Peak area | HAHA | IFN-G |